Schering Nasonex indication
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
An expansion of the Nasonex (mometasone) seasonal and perennial allergic rhinitis indication to include children two and older clears FDA July 17. The corticosteroid nasal spray was previously indicated for use in adults and children age three and olde